Cardiocel was initially used for the congenital heart market. The next and by far bigger market
is for the adult area especially mitral valve repair. Our rival is in 800 hospitals in the USA
due to this area of use.
The big sales will be in this area for which we already have approval.
The dural patch is exciting but a little time off for sales. The approval process will cost a bit as well.
An even bigger possibility will be the area of adapt for coronary arteries off the shelf. I suspect they may be $5000
a pop.
Cardiocel was initially used for the congenital heart market....
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |